Leo Pharma to test tralokinumab with new device in phase III study
Although Leo Pharma’s atopic eczema treatment tralokinumab was only recently approved by the FDA 8 months behind schedule, the company is now initiating a late-stage study to investigate the drug with a new device. A syringe component was originally behind the delay.
by ULRICH QUISTGAARD, translated by daniel pedersen
The US Food and Drug Administration (FDA) approved Leo Pharma’s great growth hope, tralokinumab, shortly before the New Year. Leo Pharma is now beginning to roll out the drug in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
